<DOC>
	<DOCNO>NCT01099488</DOCNO>
	<brief_summary>The purpose study develop immunological assay blood sample .</brief_summary>
	<brief_title>A Study Healthy Adults Having Received Single Vaccine Administration Support Development Immunological Assays</brief_title>
	<detailed_description>This clinical study vaccine administer . It design research purpose develop immunological assay .</detailed_description>
	<criteria>Subjects investigator believe comply requirement protocol ( e.g . return followup visit ) . A male female , include , 18 50 year age study start . A subject receive Yellow Fever ( YF ) vaccine day study entry . Written inform consent obtain subject . Healthy subject establish medical history clinical examination perform day YF vaccination . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior study start , agree continue adequate contraception entire study period . Use investigational nonregistered product ( drug vaccine ) within 30 day precede study start , plan use study period . Concurrently participate another clinical study , within 3 month precede study start time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Clinically significant anaemia know condition per medical history would preclude draw blood describe protocol . Known previous infection YF virus . Previous vaccination YF approximately 5 hour blood sample Visit 1 . Administration immunoglobulins and/or blood product within 3 month precede study start plan administration study period . Chronic administration ( defined 14 day total ) immunosuppressant immunemodifying drug ( include chloroquine ) within six month prior study start . For corticosteroid , mean prednisone â‰¥ 10mg/day , equivalent . Inhaled topical steroid allow . Receipt live attenuate vaccine YF vaccine period begin 30 day precede blood sample Visit 1 plan use study blood sample Visit 2 . Receipt inactivate influenza vaccine ( seasonal pandemic ) period begin 21 day precede blood sample Visit 1 plan use study blood sample Visit 2 . History malignancy ( unless surgical excision follow sufficient observation period , least 5 year , give reasonable assurance sustain cure , estimate investigator , likely recur study period ) . Any confirm suspect immunosuppressive immunodeficient condition ( include HIV , hepatitis B hepatitis C ) , base medical history physical examination ( laboratory testing require ) . Family history congenital hereditary immunodeficiency . Major congenital defect serious chronic illness . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination medical history . Acute disease and/or fever time enrolment . Known pregnant lactate female , per medical record . Female plan become pregnant planning discontinue contraceptive precaution . History chronic alcohol consumption and/or drug abuse . Any condition may preclude compliance study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Immunological assay</keyword>
</DOC>